HER-2 positive

“Evolving Landscape of Targeted Treatment Options for HER2-Positive Gastric/Gastroesophageal Adenocarcinomas” by Raisa Epistola, MD, Joseph Chao, MD, and Jennifer Lee, MD https://t.co/lPI7BsMr8o @JoeChaoMD @HarborUCLA @cityofhope (@clinadvances)

Enhertu improves survival endpoints in HER2-positive solid tumour trial, say @AstraZeneca and Daiichi Sankyo, raising hopes of 'tumour-agnostic' label. #oncology https://t.co/YHbNvWQMUe (@pharmaphorum)

#Tucatinib + #Trastuzumab was approved earlier this year for refractory mCRC HER 2 positive disease. Previously, we had also discussed the implications of anti-egfr therapy w/ @GIcancerDoc and @CathyEngMD in this subset + RAS WT. This study by @GIcancerDoc continues to support:… https://t.co/16FDqtJdMS (@OncBrothers)

Terrific presentation on opportunities and unmet needs in HER2-positive breast cancer by @stolaney1 at #IBCEast. An expanding pipeline of anti-HER2 agents and the development of helpful biomarkers is allowing for a progressive increase in the tailoring of our treatments. (@PTarantinoMD)

Newly Approved and Emerging Agents in HER2-Positive Metastatic Breast Cancer - @DrSGraff #oncodaily #oncology #CancerResearch #HER2 https://t.co/h22k90nufb (@oncodaily)

Now in ⁦@CBCjournal⁩: Newly Approved and Emerging Agents in HER2-Positive Metastatic Breast Cancer, with ⁦@YAbdouMD⁩ and #FengtingYan I love the way the figures turned out—will share them over the coming days! #bcsm https://t.co/TNFnI1a4qI (@DrSGraff)

Newly Approved and Emerging Agents in HER2-positive MBC 👇🏼 #bcsm #CBCjournal @YAbdouMD @DrSGraff (@CBCjournal)

📣 Dr. John L. Marhsall (@marshalj23) explains how to incorporate into practice the latest data on #HER2-positive gastric/gastroesophageal junction #cancers ✅ Updating healthcare professionals' know-how in the use of data is key for the benefit of #patients (@FundacionECO)

Yes definitely using in carcinosarcoma. What about advanced serous HER2 positive? Thoughts about IO vs trastuzumab? (@LAMcAlarnenMD)

In the Medical Spotlight: Antibody-Drug Conjugates in Advanced HER2-Positive Gastric/Gastroesophageal Junction Cancer with @marshalj23, @LizzySmyth1, and @mariglesiascoma. https://t.co/4Nyo8pdq1Q via @ReachMD (@RueschCenter)

Dr. Manish Shah (@mdmanishshah) is presenting on managing HER2-positive metastatic #GastricCancer/#GastroesophagealCancer @NACECME’s #ConversationsInOncology virtual conference this weekend. Learn more and register to earn #CME credit: https://t.co/3RCKzVpEE2 (@WCMGIcancer)

34F, Rt multicenteric BCA, HER2 + TNBC. S/p ddAC+ T+H+P ->SM + SLN -> mpT1cN0. HER2 positive lesion not seen. How to select adjuvant Rx ? HERCEPTIN + capacitabine? @stolaney1 @IlanaSchlam @HemOncFellows @DFCI_BreastOnc (@Arif_Hameed)

Congrats to ⁦@FAndreMD⁩ et al! ⚽️🥅 👉🏼Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial ⁦@TheLancet⁩ https://t.co/4Bu9eUfFA8 (@VivekSubbiah)

all the metastatic hormone positive her2 negative breast cancers don’t benefit from CDK4/6 inhibitors in front line! Speaker: Barbara Pistilli #florencebreast23 @OncoAlert @acampsmalea @ChelainG @MartaPerachino @FatjonaKrajaMD @FrancicaPaola (@Dr_m_garousi)

New 📰published in @Annals_Oncology on the association of #HER2DX with pathological complete response and survival outcomes in #HER2-positive #BreastCancer. @G_Villacampa @stolaney1 @EMittendorfMD @prat_aleix @adawaksmd @vitti10 @awolff @patri0608 @sltc21 https://t.co/6RBjvvkGmI (@DFCI_BreastOnc)

Q7: What happens to HER2 expression in residual disease following neoadjuvant therapy in patients with HER2-positive breast cancer? #asco23 https://t.co/OpQKvhiQcB #HER2low #PathTwitter, #BreastPath @feldmanm30 @Baskotacytopath @DrBuiPathology @drshiwei (@ASCP_Chicago)

Here, Paolo Tarantino, MD, discusses discoveries made in the genomic characterizations and treatment of HER2-low, HER2-zero, and HER2-positive breast cancers, which he presented at the San Antonio Breast Cancer Symposium. https://t.co/Iie4Qc3BLM @DanaFarber @PTarantinoMD #SABCS (@OncLearnNetwork)

New in #npjBCancer, @FilipaLynce @IBC_DanaFarber demonstrated in a cohort study that patients with de novo HER2-positive metastatic inflammatory #BreastCancer have favorable outcomes and there may be a role for local therapy for these patients. https://t.co/u7Vn9CFvN5 (@Nature_NPJ)

Zanidatamab could potentially treat HER2 positive biliary tract cancer. "It's not a curative option for our patients, but it definitely does give them long-term disease control," says our Dr. Shubham Pant. https://t.co/85c5DhK7fL @HealthDayTweets @DrShubhamPant #EndCancer (@MDAndersonNews)

Lisa A. Carey, MD, and Javier Cortes, MD, PhD, on HER2-Positive Early Breast Cancer: Chemotherapy De-escalation Under Study in PHERGain Trial https://t.co/MbnePsmcDo #bcsm #breastcancer #oncology #ASCO23 @DrLisaCarey @UNC_Lineberger @JavierCortesMD (@ASCOPost)

3️⃣0️⃣ de junio | "In the Medical Spotlight: Antibody-Drug Conjugates in Advanced HER2-Positive Gastric/Gastroesophageal Junction Cancer" 📍 @CCIB_Forum (Barcelona) 🕒 13:30h a 15:00h 👨 Con @marshalj23, @mariglesiascoma y @LizzySmyth1 Inscríbete 👇 https://t.co/22GnsTOJ39 (@FundacionECO)

Check out Dr. Michail Ignatiadis @MIgnatiadis @JulesBordet discussing #ASCO23 Primary Efficacy Analyses of NeoRHEA, #Neoadjuvant #Biomarker Research Study of Palbociclib w/Endocrine Therapy in Estrogen Receptor Positive/HER2- BC #bcsm #breastcancer @EORTC https://t.co/iwysbmWmEj (@Sameh_VuMedi)

Recently published📰in @Nature_NPJ Breast by Dr. Ana Garrido-Castro and colleagues👉Clinical outcomes of de novo metastatic HER2-positive inflammatory breast cancer #IBC https://t.co/W3HuMXNUgs @FilipaLynce @Merregan @RosenbluthLab @jenniferbellon2 @stolaney1 @nlinmd (@DFCI_BreastOnc)

Final overall survival (OS) analysis from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) in patients (pts) with hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC). @stolaney1 Summary: https://t.co/EhtJ4vYzX0 #ASCO23 #bcsm (@paspears88)

Breast Cancer Research: Final results of TROPiCS-02 reported at #ASCO23. Data shows antibody-drug conjugate offers significant survival benefit for patients with HR-positive/HER2-negative metastatic breast cancer Read more ➡️ https://t.co/mBMz5ZnZox CC: @DFCI_BreastOnc @STolaney1 (@DanaFarberNews)

Zanidatamab demonstrated antitumor activity, including rapid and durable responses in patients with treatment-refractory HER2-positive biliary tract cancer @DrShubhamPant (@VibhaJayaraj)

Our Dr. Kanwal Raghav presented at #ASCO23 a study he led that demonstrated promising antitumor activity with the use of trastuzumab deruxtecan for patients with HER2-positive metastatic colorectal cancer. https://t.co/PUUSItVdMd @kanwal_raghav @ASCO #EndCancer (@MDAndersonNews)

Presented at #ASCO23 very important data from the #SOFT trial to increase our understanding of the biology of hormone receptor-positive/HER2-negative #BreastCancer in premenopausal women: congratulations @LoiSher @etop_ibcsg et all! @OncoAlert (@matteolambe)

Tucatinib plus trastuzumab for previously treated metastatic BTC with Her2 positive. Median PFS of 5.5 months. @ASCO @agrothey @GIcancerDoc #ASCO23 (@SuyogCancer)

Lerociclib/Fulvestrant May Reduce Risk of Disease Progression in Advanced HR-Positive/HER2-Negative Breast Cancer https://t.co/TWzsHInxAr @ASCO #ASCO23 @glopesMD (@GlopesMd)

Ahead of #ASCO23, check out our review on the current landscape of HER2-positive metastatic breast cancer ➡️ @YAbdouMD @FengtingYan @CBCjournal #bcsm Newly Approved and Emerging Agents in HER2-Positive Metastatic Breast ... https://t.co/BOKSV95ajs (@DrSGraff)

#Breastcancer #HER2 #resistance 📢 The change of paradigm in the treatment of HER2-positive breast cancer with the development of new generation antibody-drug conjugates 👉https://t.co/s2H2551oR6 @DrHBurstein @teamoncology @NBCCStopBC @DrSGraff @BreastDocUK @StoverLab @Debeblab (@cdrjournal)

The TOT-HER3 study investigated HER3-DXd in previously untreated HR+positive/HER2- tumors early breast cancer in cohorts with different ERBB3 mRNA expression levels. Change in CelTIL score was the primary endpoint https://t.co/6Py1TBx9sv @_SOLTI @MOliveira_MD @prat_aleix #bcsm (@Annals_Oncology)

I had HER2 positive breast cancer and didn’t know it was the most common ! Am I right in thinking it’s more aggressive ? (@WendyHoban74)

My co-chair of #ABC20203 and moderator of session 2 @drmediget Dr Senthil Damodaran - taking a little break between HER2 positive vs negative #bcsm ! @MDAndersonNews @BCMCancerCenter (@naborala)

Brilliant Dr Garrido-Castro @DanaFarber starts her marathon of one of the most important advancement of #bcsm HER2 positive and low ABC including the review of Antibody-drug conjugate (@naborala)

#ESMOBreast23 HER2DX and pathological complete response in HER2-positive breast cancer: a combined analysis of 4 neoadjuvant studies 💥HER2DX may assist in the selection of neoadjuvant therapy in HER2-positive BC. Presented by Dr. Adrienne Waks @OncoAlert @myESMO (@dr_yakupergun)

Dr @hoperugo offers detailed analysis of safety & adverse events with T-DXd on Destiny Breast 04 in HER2 Low breast cancer. 🔑 key takeaway: tolerable safety signal similar to what we know from the treatment of HER2 positive breast cancer #ESMOBreast23 @OncoAlert (@DrSGraff)

In 2023, theres a case for just making some cisplatin and carboplatin for lung cancer, her2 positive breast cancer, and triple negative breast cancer. Id hate to have to find the drug to treat CNS mets that could have been cured if they had received optimal adjuvant therapy (@SyedMAhmedMDPhD)

Tucatinib plus trastuzumab is a new treatment option for chemotherapy-refractory HER2-positive/RAS wild-type metastatic colorectal cancer-MOUNTAINEER https://t.co/GX61FjXMH7 (@drkpavithran)

Recently published in @JAMAOnc: Assessment of a Genomic Assay in Patients With ERBB2-Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy With or Without Pertuzumab. Congrats @adawaksmd @stolaney1 @EMittendorfMD and colleagues! #breastcancer #bcsm (@DFCI_BreastOnc)

Characteristics, treatment and outcomes of HER2 positive male 🧔‍♂️👨🏽‍🦳👨🏿‍🦱 breast cancer 🩻🚨⏰⤵️ #SoMe4Surgery @SWexner @juliomayol @PipeCabreraV @Cirbosque @pferrada1 @TomVargheseJr @herbchen @ascolcirugia Link: https://t.co/aA0TfrrXW3 (@AmJSurgery)